Aurimi Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
5
Aurimi Therapeutics General Information
Description
Developer of a biotechnology platform designed to build drug molecules for the specific blockade of autoimmune disease-associated antibodies. The company's platform screens compounds for optimal docking within human leukocyte antigens, together with rational drug design and bioassays to build targeted therapeutic candidates, enabling patients and health professionals to detect early signs across autoimmune diseases.
Contact Information
Website
www.aurimitx.comCorporate Office
- 299 Washington Street
- Suite A
- Woburn, MA 01801
- United States
Corporate Office
- 299 Washington Street
- Suite A
- Woburn, MA 01801
- United States
Aurimi Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 5. Later Stage VC (Series A) | 30-Oct-2020 | Completed | Generating Revenue | |||
| 4. Early Stage VC (Series A) | 09-Oct-2019 | Completed | Startup | |||
| 3. Angel (individual) | 03-Aug-2016 | Completed | Startup | |||
| 2. Angel (individual) | 30-Jun-2015 | $500K | $500K | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2015 | Completed | Startup |
Aurimi Therapeutics Comparisons
Industry
Financing
Details
Aurimi Therapeutics Competitors (47)
One of Aurimi Therapeutics’s 47 competitors is Second Genome, a Formerly VC-backed company based in Brisbane, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Second Genome | Formerly VC-backed | Brisbane, CA | ||||
| Enterome | Venture Capital-Backed | Paris, France | ||||
| AnTolRx | Formerly VC-backed | Cambridge, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| CSL Behring | Corporation | King Of Prussia, PA |
Aurimi Therapeutics Patents
Aurimi Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023287740-A1 | Compounds and methods for treating autoimmune disorders by targeting hla-dq2 | Inactive | 16-Jul-2021 | ||
| EP-4267123-A1 | Methods for producing d-?-methyldopa | Pending | 23-Dec-2020 | ||
| EP-4267123-A4 | Methods for producing d-?-methyldopa | Pending | 23-Dec-2020 | ||
| US-20220194893-A1 | Methods for producing d-alpha-methyldopa | Active | 23-Dec-2020 | ||
| US-11702383-B2 | Methods for producing d-α-methyldopa | Active | 23-Dec-2020 | C07C227/02 |
Aurimi Therapeutics Signals
Aurimi Therapeutics Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CU Healthcare Innovation Fund | Corporate Venture Capital | Minority | ||
| Morningside Group | Venture Capital | Minority | ||
| T1D Fund | Venture Capital | Minority | ||
| University of Florida | University | |||
| C2I Accelerator | Accelerator/Incubator |
Aurimi Therapeutics FAQs
-
When was Aurimi Therapeutics founded?
Aurimi Therapeutics was founded in 2015.
-
Where is Aurimi Therapeutics headquartered?
Aurimi Therapeutics is headquartered in Woburn, MA.
-
What is the size of Aurimi Therapeutics?
Aurimi Therapeutics has 4 total employees.
-
What industry is Aurimi Therapeutics in?
Aurimi Therapeutics’s primary industry is Drug Discovery.
-
Is Aurimi Therapeutics a private or public company?
Aurimi Therapeutics is a Private company.
-
What is Aurimi Therapeutics’s current revenue?
The current revenue for Aurimi Therapeutics is .
-
How much funding has Aurimi Therapeutics raised over time?
Aurimi Therapeutics has raised $17.9M.
-
Who are Aurimi Therapeutics’s investors?
CU Healthcare Innovation Fund, Morningside Group, T1D Fund, University of Florida, and C2I Accelerator have invested in Aurimi Therapeutics.
-
Who are Aurimi Therapeutics’s competitors?
Second Genome, Enterome, AnTolRx, Adaptimmune Therapeutics, and CSL Behring are some of the 47 competitors of Aurimi Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process